Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$173.04 USD

173.04
1,581,725

-0.88 (-0.51%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Alkermes (ALKS) Reports Wider-Than-Expected Loss in Q1

Alkermes (ALKS) posts wider than expected loss in the first quarter of 2018. However, sales beat estimates.

    Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales

    The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.

      Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down

      Biogen's (BIIB) earnings beat estimates but sales miss the same marginally in Q1. The company's latest key drug Spinraza's tepid sales compares with its sequential tally.

        Biogen (BIIB) Q1 Earnings Beat, Sales Miss

        Biogen (BIIB) beat estimates for earnings but marginally misses the same for sales in Q1. The company's oral MS drug Tecfidera sales increased year over year.

          Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus

          Roche (RHHBY) announces encouraging data on multiple sclerosis (MS) drug Ocrevus which reinforced the efficacy of drug in the long run.

            Novartis (NVS) Reports Encouraging Data on MS Candidate

            Novartis (NVS) announces encouraging results from a phase III study, EXPAND, on siponimod (BAF312) in patients with secondary progressive multiple sclerosis.

              What's in Store for Biogen (BIIB) This Earnings Season?

              On the Q1 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance.

                Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar

                Mylan (MYL) is partnering with Fujifilm Kyowa to commercialize a biosimilar to Humira (adalimumab).

                  AbbVie's RA Candidate Meets Primary Endpoints in Phase III

                  AbbVie's (ABBV) rheumatoid arthritis candidate, upadacitinib, meets both primary and secondary endpoints in the fourth phase III SELECT study for the given indication.

                    Novartis Inks $8.7 Billion Gene Therapy Deal to Buy AveXis

                    Novartis (NVS) signs a contract to purhcase the U.S. based clinical stage gene therapy company, AveXis, Inc for a cash-tender offer of $218 per share.

                      Biogen Cracks the Case With AbbVie for Humira Biosimilar

                      Biogen (BIIB) and partner Samsung Bioepis resolve an ongoing patent row with AbbVie regarding Biogen's biosimilar version of AbbVie's arthritis drug, Humira, in the EU.

                        The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene

                        The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene

                          Why Multiple Sclerosis is a Promising but Risky Space?

                          Multiple Sclerosis (MS) is a promising space but risks continue to persist with the recent withdrawal of Zinbryta.

                            Kevin Cook headshot

                            Bull of the Day: Regeneron (REGN)

                            Key pharma franchises in a bustling pipeline have shares looking attractive again at 17X and 15% EPS growth

                              Biogen to Buy Mid-Stage Neuropsychiatry Asset From Pfizer

                              Biogen (BIIB) agrees to pay $75 million upfront to buy mid-stage candidate from Pfizer, which is being developed for cognitive impairment associated with schizophrenia (CIAS).

                                PDL BioPharma (PDLI) Q4 Earnings Beat, Revenues Rise Y/Y

                                PDL BioPharma's (PDLI) earnings top estimates in Q4. Revenues also grow year over owing to rise in royalty rights.

                                  Are Alzheimer's-Focused Stocks Set for a Financial Windfall?

                                  Launch of the blood tests will help companies focused on developing preventive treatments make billions.

                                    Biogen (BIIB) Down 17.2% Since Earnings Report: Can It Rebound?

                                    Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                      What's in the Cards for Ionis (IONS) This Earnings Season?

                                      Ionis Pharmaceuticals (IONS) earns $70 million in milestone and license payments from several drug companies. Spinraza witnesses strong fourth quarter as announced by Biogen in its earnings release.

                                        Ionis Out-Licenses Second Candidate to AstraZeneca, Earns $30M

                                        Ionis Pharmaceuticals (IONS) out-licenses Generation 2.5 antisense drug to AstraZeneca under a strategic collaboration agreement.

                                          Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat

                                          Acorda (ACOR) misses on earnings in Q4 but beats on revenue estimates. The company's key drug Ampyra witnesses an increase in sales both year over year and sequentially.

                                            FDA Sets the Stage for Earlier-Stage Alzheimer's Treatments

                                            FDA's proposed guidelines come in a week when major disappointments in the field were announced by companies developing drugs to treat Alzheimer's.

                                              Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates

                                              Alkermes (ALKS) tops earnings and sales estimates in the fourth quarter of 2017 on the back of strong growth of Vivitrol and Aristada. The company provided a decent outlook for 2018.

                                                Merck (MRK) Halts Another Late Stage Study on Alzheimer's

                                                Merck (MRK) stalls a phase III study evaluating verubecestat for the treatment of prodromal Alzheimer's disease on the recommendation of an external data monitoring committee.

                                                  The Zacks Analyst Blog Highlights: Novartis, BP and Biogen

                                                  The Zacks Analyst Blog Highlights: Novartis, BP and Biogen